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Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while
being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly
used in the treatment of several types of leishmaniasis. Aims. The eﬃcacy of a topical liposomal amphotericin B formulation was
compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly
selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3–7 drops twice daily, according to the
lesion’s size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2mL once a week for
the same period. The clinical responses and side eﬀects of both groups were evaluated weekly during the treatment course. Results.
Per-protocol analysis showed no statistically signiﬁcant diﬀerence between the two groups (P = 0.317, 95% conﬁdence interval
(CI) = 1.610 (0.632–4.101)). Moreover, after intention-to-treat analysis, the same results were seen (P = 0.650, 95% CI = 0.1.91
(0.560–2.530)). Serious post treatment side eﬀects were not observed in either group. Conclusions. Topical liposomal amphotericin
B has the same eﬃcacy as intralesional glucantime in the treatment of cutaneous leishmaniasis.
1.Introduction
Leishmaniasis is a major world health problem, which is
increasing in incidence. The diagnosis is often made on the
basis of a clinically typical lesion in conjunction with an
appropriate history of exposure [1]. Although cutaneous
leishmaniasis (CL) is a spontaneously resolving disease
usually within a year, the resulting disﬁgurement and the
duration of the disease require an eﬀective treatment [2].
A wide range of therapeutic options have been employed
over the years but its optimal treatment is not yet known
whereas drug resistance is becoming an increasing problem
in countries of leishmaniasis endemicity [3].
AmphotericinB(AmB),apolyeneantibioticandthegold
standard for systemic fungal infections, also has excellent
antileishmanial activity. Due to the higher aﬃnity of AmB
for 24-substituted sterols, aqueous pores are formed in
the membrane leading to increased membrane permeability
and killing of Leishmania [4]. It is commonly administered
intravenously as an alternative treatment in visceral and
mucocutaneous leishmaniasis [5–7]. In a mouse model it
has been shown that topical AmB as a complex either with2 Journal of Parasitology Research
cholesteryl sulfate or with phospholipids in the presence of
ethanol canpenetrate into the skin andcure CL in alocalized
manner using a very low total drug concentration [8]. In
another study topical AmB was proven to be eﬀective against
CL caused by Leishmania major [9]. Since liposomal AmB
is administered topically, it could be considered as a good
alternative in the treatment of CL.
In the present study we aim to compare the therapeutic
eﬀects of a formulation of topical liposomal AmB with
intralesional glucantime in the treatment of CL.
2.MaterialandMethods
This clinical trial was carried out on CL patients who
visited the dermatology clinic from March 2008 through
September 2010 in Ghaem Hospital, Mashhad, Iran, where
CL is endemic and 96.5% of CL cases are caused by L. tropica
and less commonly L. major [10, 11]. 110 patients with the
clinical diagnosis of CL were recruited and were completely
informed of the study goals and had ﬁlled in the consent
required to participate in the trial, which was also approved
by the ethics committee of Mashhad University of Medical
Sciences.
The inclusion criteria were
(i) patients with cutaneous leishmaniasis approved by
either a direct smear stained with Giemsa or a posi-
tive skin biopsy of lesions with less than 6-month
duration,
(ii) in cases with a previous history of anti-leishmaniasis
therapy, a 3-month treatment-free interval from the
last treatment course was taken into consideration.
The exclusion criteria were
(i) pregnancy,
(ii) breastfeeding,
(iii) taking any other speciﬁc treatment while participat-
ing in the study,
(iv) past medical history of any local or systemic disease
during the last 2 months,
(v) asigniﬁcantunderlying diseasesuchascardiac,renal,
or liver dysfunction.
The information collected from each patient included
demographic data and characteristics of their disease.
The 110 patients who met our inclusion criteria were
randomly divided into two groups. Liposomal AmB was
administered for 50 patients while the other 60 received
intralesional glucantime.
In the ﬁrst group liposomal AmB was administered as 3–
7 drops twice daily according to the lesion size. In the second
group intralesional glucantime (Glucantime; Specia, Paris,
France) was injected into each lesion once a week, to the
point when the lesion’s surface became fully inﬁltrated and
up to a maximum dose of 2mL.
Clinical response was determined on the basis of the
lesionindurationsizeofandtheextentofre-epithelialization
in ulcerative ones on every follow-up visit. The treatment
periodwasdecidedas8weeksforeachgroupandthepatients
were followed up weekly during the treatment course while
the changes in the lesion induration size and side eﬀects were
recordedineverysession.Thepatientswerealsostudiedonce
again, 6 months after termination of the treatment course.
The therapeutic results were classiﬁed as follows:
(a) slight improvement: decrease in induration size up to
25%,
(b) mild improvement: decrease in induration size be-
tween 25 and 50%,
(c) moderate improvement: decrease in induration size
between 50 and 75%,
(d) marked improvement: decrease in induration size
more than 75%.
2.1. Materials. Egg lecithin, cholesterol, glucose, oleic acid
and AmB (formulated with deoxycholate) (250µg/mL) were
purchased from Sigma-Aldrich.
2.2. Equipments. The equipments employed included a
transmission electronic microscope (LEO 912 AB, Ger-
many), freeze drier (Labcon Co., USA), Spectrophotometer
(UV-160A Shimatzu, Japan) and a Particle size analyzer
(PSA) (Klots, Germany).
Multilamellar large vesicle (MLV) liposomes containing
AmB were prepared through the freeze-drying method.
2.3. Method. The method was based on the formation of
a homogenous dispersion of lipids in water-soluble carrier
materials. To obtain the lipid-containing solid dispersion,
liposome-forming lipids and water-soluble carrier materials
with AmB were dissolved in t-Butyl alcohol/water cosolvent
systems to form an isotropic monophase solution, and
then the resulting solution was frozen and lyophilized after
sterilizationbyﬁltrationthrough0.2µmpores.Addingwater
to the lyophilized product besides hard shaking followed
by sonication spontaneously forms a homogenous liposome
preparation.
For the formation of monophase solution and sterile
ﬁltration, egg lecithin (375mg), cholesterol (125mg), and
oleic acid (25mg) were dissolved in t-Butyl alcohol, while
glucose (500mg) and AmB were dissolved in water. Then
thesetwosolutionsweremixedtogetherinappropriateratios
(1:1) to give a third clear isotropic monophase solution.
After the monophase solution was sterilized by ﬁltration
through 0.22µm pores, it was ﬁlled into the 100mL freeze-
drying ﬂask vials with a ﬁll volume of 10.0mL [12].
2.4. Freeze-Drying. The freeze-drying process was as follows:
(1) freezing at −40◦C for 8hrs; (2) primary drying at −40◦C
for 24hrs; (3) secondary drying at 25◦C for 10hrs. The
chamber pressure was maintained at 20 Pascals during the
drying process. Note that, lyophilized products can be stored
for a long period of time under the dry ambient providing it
is well sealed.Journal of Parasitology Research 3
Reconstitution. Lyophilized products can be reconstituted
by adding 10mL of AmB solution (250µg/mL) and gentle
sterilewaterwithhardshakingfollowedbysonication,which
will lead to the formation of the aqueous suspensions of
homogeneous liposomes.
2.5. Results. The encapsulation capacity of the liposome was
found to be 81.4 ± 3.12% by the UV spectroscopic method,
indirectly. The average particle size, which was measured by
PSA was 2.21µm( P d I= 0.254).
2.6. Safety Measurements. The possible transdermal passages
of AmB into blood circulation were previously ruled out [9].
The apparent volume of distribution of liposomal form of
AmB is reported to be 0.1–0.44lit/kg while the maximum
therapeutic concentration of this drug is about 1–1.5mg/kg
[13]. Liposomal formulation of AmB contains 5mg of active
ingredientper1mLofsolution;supposingeachdropvolume
(0.05mL) involved 0.25mg amphotericin, the amount of the
drug in 2 drops (one dose of treatment) would be equivalent
to 0.5mg of active ingredient.
Considering the apparent volume of distribution [14],
the drug concentration in the plasma of a 70kg person will
be between 0.016 and 0.07mg/lit, which is less than the
maximum therapeutic dose for this drug (2.26–10mg/lit).
2.7. Sample Size. To detect a 35% diﬀerence in the cure rate
between the two groups of liposomal AmB and glucantime,
assuming a 90% cure rate in liposomal AmB group with a
95% power and a 5% two-sided type I error, 36 subjects were
required in each group. Also regarding a loss to follow up of
2 0 % ,t h i sn u m b e rr a i s e dt o5 0p a t i e n t sf o re a c hg r o u p .
2.8. Statistical Analysis. Two diﬀerent approaches were per-
formed to compare the treatment outcomes between the
two groups. The ﬁrst approach was an intention-to-treat
analysis that included all the 110 patients enrolled at the
beginning of the trial and considered patients with irregular
treatments and followups as therapeutic failures. The second
was more stringent and solely included the 76 patients with
regular treatments and followups. They were considered
as good compliers and better represented an explanatory
approach which allowed the interpretation of data in terms
of eﬀectively treated patients.
Statistical analysis was done by applying Chi-square test.
Data was expressed as mean values ± SD, and the diﬀerence
was considered signiﬁcant when P<0.05.
3. Results
Figure 1 shows the ﬂow of participants in our study. During
the study, 11 patients in the liposomal AmB and 23 in the
glucantime groups were excluded due to taking two treat-
mentmethods simultaneously, notcompleting thetreatment
course, changing their home, and losing access for further
followup while 76 completed the study including 39 in the
study group (liposomal AmB) and 37 in the control group
110 patients
50 topical liposomal
AmB
60 intralesional
glucantime
39 adhered to
treatment
23 did not adhere
39 attended to
the 6months
11 did not adhere
37 adhered to
treatment
37 attended to
the 6months
Figure 1: The ﬂow of participants through each stage of our study.
Table 1: Demographic and cutaneous leishmaniasis characteristics
of the studied population.
Intralesional
glucantime
Liposomal
amphotericin B
P value
No. of patients 60 50
Sex
Male 21 23 0.241
Female 39 27
Age
(mean ± SD) 25.30 ± 15.70 20.54 ± 18.72 0.150
No. of lesions 1.4 ± 0.76 1.91 ± 1.02 <0.05
(mean ± SD)
Duration of lesions
(week)
3.84 ± 1.75 4.24 ± 1.24 0.166
Type of lesions
Papuloplaque 53 33
0.011 Nodule 5 8
Ulcer 2 9
Location of lesions
Head and neck 22 26
0.185 Hand 32 18
Leg and trunk 6 6
(intralesional glucantime). Demographic characteristics of
the patients in both groups have been shown in Table 1.
According to these data, the two groups were matched
for sex, age, number of lesions, lesion duration, type, and
location (P>0.05) but varied in the type and number of
lesions which was a slightly higher number of papule and
plaque lesions in the glucantime group.
The most common lesion site in all the studied cases was
the upper limbs (hand and forearm: 45.4%) and the head4 Journal of Parasitology Research
Table 2: Comparison of therapeutic response rates in the studied groups using the intention-to-treat approach and per-protocol analysis.
Proportion (%) of patients with cure at 8 weeks
Analytical assumptiona AmB group GL group OR (95% CI) P
(AmB versus GL)
Per protocol 22/39 (56.4) 25/37 (67.6) 1.610 (0.632, 4.101) 0.317
ITT 22/50 (44.0) 29/60 (48.3) 1.91 (0.560, 2.530) 0.650
GL: glucantime; AmB: liposomal amphotericin B; ITT: intention-to-treat; OR: odds ratio; CI: conﬁdence interval.
aPer protocol: analysis excluding patients that were lost to follow up, ITT: analysis including patients lost to follow up throughout the study, who were
considered to have experienced treatment failure.
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Figure 2: Improvement rate of the two groups based on change in
induration size of lesions.
andneck(face:43.6%),respectively,whilethemostcommon
lesion type in both groups was papule and plaque (78.2%).
No signiﬁcant diﬀerence in the treatment response
between the males and females was seen in either group
(P = 0.840). Figure 2 compares the improvement rate
of both groups based on changes in induration size, and
Table 2 summarizes the results of the intention-to-treat
approach and the analysis of “compliers only,” comparing
therapeutic failure rates. Serious posttreatment side eﬀects
were not observed in either group. 7 patients (11.7%) in
the glucantime group showed erythema and edema at the
injection site which were managed with a cold compress and
antihistamine drugs and they all completed the treatment
course. In the latter group only 1 patient (1.7%) complained
of hypersensitivity. Also 5 patients (10%) in the AmB group
showed mild pruritus around the lesions. Upon 6 months
of follow-up, no recurrence of the disease was noted in the
cured patients of either group.
4. Discussion
Mashhad located in the Northeast of Iran is endemic for
cutaneous leishmaniasis mainly caused by L. tropica and
less commonly L. major [10, 11, 15]. Pentavalent anti-
moniates have long been the most common treatment for
leishmaniasis in our region, but acquired drug resistance
towards them has increased during the recent years [16, 17],
raising a strong need for new anti-leishmaniasis treatments.
Knowing the fact that CL is a self-limiting disease, the
main goal in its treatment would be controlling the spread
of the disease in endemic regions besides decreasing scar
formation; therefore it would be more logical to use safe
topical drugs in order to prevent any adverse reactions.
Systemic liposomal AmB has been recently administered in
the treatment of drug-resistant cutaneous leishmaniasis [18–
20]. Preliminary results have shown that topically applied
lipid-based formulations containing AmB have a signiﬁcant
therapeutic eﬀect in the treatment of CL lesion in adults.
Zvulunov et al. even reported successful treatment of a 1.5-
year-old infant with persistent CL by the administration of
a topical colloidal solution of AmB for 3 weeks [21]. In a
study conducted in 1999 on the treatment outcome of two
similar lesions of the same individual, the topical liposomal
AmB-treated lesions showed signiﬁcant improvement with
noevidenceofrelapsewhencomparedtotheplacebo-treated
ones [9]. Another study taking place in Israel on 19 patients
receiving 2 vials, one containing AmB-cholesteryl sulfate
dispersed in a 5% ethanol solution and one with 5% ethanol
in water for half of each patient’s lesions, the results revealed
a better therapeutic response in those lesions treated with
topical liposomal AmB in comparison to placebo [22].
Although several studies have been performed on the
eﬃcacy of topical AmB on CL, this study is the ﬁrst which
compares its eﬀect with intralesional glucantime; moreover,
sample size of our study is not comparable with other similar
ones.
In the present study, comparing the eﬀect of AmB and
intralesional glucantime on leishmania lesions, no signi-
ﬁcant diﬀerence was observed (56.4% versus 67.6%, P =
0.317), indicating that topical AmB has a similar eﬃcacy
to intralesional glucantime. Although preparing topical
liposomal AmB as a therapeutic drug is neither easy nor
inexpensive, because of its simple, painless administration
route by the patient himself, no transdermic passage into
blood circulation causing less toxicity, and no need for
recurrent visits, AmB could be considered as an alternative
treatment especially in children who do not tolerate painful
methods, patients who cannot make recurrent visits, and in
cases where glucantime is contraindicated or unresponsive.
Evaluating the eﬀect of a drug on a self-limiting disease,
in particular, considering the fact that variability in the dis-
ease length in diﬀerent individuals can be of several months,
would be quite diﬃcult; therefore a study in which patients
with two similar leishmania lesions could simultaneously
receive both treatments (AmB and glucantime) is highly
recommended in further studies on this issue.Journal of Parasitology Research 5
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